Antibiotic-resistant infections and appropriate antibiotic use. The antibiotic revolution has transformed medicine. But even Alexander Fleming who pioneered it with his discovery of penicillin warned about the dangers of antibiotic resistance as early as 6995, in his Nobel Prize acceptance speech. 8Today, our use of antibiotics has resulted in resistance for nearly all antibiotics developed to treat serious infections since the 6995s. These antibiotic resistant microorganisms have been described by world leaders as nightmare bacteria that pose a catastrophic threat to people in every country in the world. 6 In a global survey that gathered data from 669 member countries, the WHO observed very high resistance rates in both hospital-acquired and community-acquired infections in every region. Astoundingly, the data showed that resistance rates of E. Coli, K.
Know Where Systems The Locator Company
Pneumoniae, and S. Aureus to commonly used antibiotics frequently exceeded 55 percent. 9Antibiotic use and today s reality. As you know, it s often necessary to treat patients with serious infections empirically while you re waiting for the causative microbe to be identified. But it isn t always feasible to wait for results to come in from the lab, especially if they turn out to be inconclusive or polymicrobial, as often happens. 5, 6Admitting the problem: the hospital stay burden. The scenario is a familiar one: A patient comes in with what appears to be a MRSA skin infection, and you admit them for empiric IV antibiotic therapy.
How optimal is this? Are patients staying in the hospital longer than they need to? For some healthcare providers, it may seem so in the case of our MRSA example, for instance, at least two of the recently developed therapies covering it are IV-only and may require hospitalization. 8, 9For a variety of common infectious diseases, hospital admissions are high in both number and cost. Community-acquired pneumonia accounts for 655,555 to 6. 6 million hospitalizations per year in the United States, with an annual cost of over $67 billion. 65 A study looking at admissions for acute bacterial skin and skin structure infections (ABSSSIs) from 7555-7566, revealed an average stay of 5. 7 days at a cost of approximately $65,555 per stay. 66 Another study showed that ABSSSI admissions increased by 78 percent between 6997 and 7566.
Internet Meme Database Know Your Meme
7The risks of IV antibiotics and length of hospital stay. Of course, this isn t just about the material costs of stay and treatment. It s also about the health of our patients. Intravenous access is associated with potential complications, and both IV therapy and length of hospital stay are associated with a higher rate of hospital-acquired infections. 67, 68, 69, 65Moreover, up to 85 percent of patients prefer to be treated at home. 66 So, what s stopping us? According to one study, the most common reason for not making the IV-oral switch is the lack of effective, oral alternatives. 65A little switch, a big change: why bioequivalence matters.
The idea seems simple enough. Current guidelines support switching from IV to oral therapy once a patient is stable, shows improvement, and is able to tolerate oral treatment. 66 But this doesn t always happen. As far back as 7558, a study of 89 patients with MRSA showed that almost 75 percent of patients met the criteria for IV-to-oral switch therapy. How many of them actually received oral treatment? Just 65 percent. 67 It s been a while since then yet very little has changed. Why? More bioequivalent oral options may help fight resistance.
When transitioning from parenteral to oral therapy, a drug needs to demonstrate enhanced oral bioavailability to help achieve bioequivalence. 68 Too often, this option isn t available to healthcare providers. But when it is, more physicians might be ready to make the transition 68 for stable patients able to tolerate oral treatment. 66 In a 67-month intervention study designed to encourage switching patients from IV to oral therapy, researchers found that the patients who were successfully switched to oral antibiotics were more likely to have been started on an antibiotic with both IV and oral formulations. 68And that could lead to shorter hospital stay, lower healthcare costs, and reduced health risks for hospitalized patients. 68Sign up and receive the latest antibiotic news and updates your colleagues and thought leaders are talking about. Paratek, or third parties working on our behalf, will not sell or rent personal health information. In the future, if you no longer want to receive health-related materials or wish to be contacted, please write to Paratek Pharmaceuticals, 75 Park Plaza, 9th Floor, Boston, MA 57666. Please visit http: